News

Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for ...
Biolife solutions reaffirms 2025 revenue guidance at $95.5M–$99M amid cell processing growth
Ooops... Something went wrong while loading this page.